Overview Dividends

(CLBT) Cellebrite DI - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011794802

Forensics Software, Extraction Tools, Analysis Platform, Case Management

CLBT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 22.57%
EPS Trend (3Y Correlation): 70.1%

CLBT Revenue

Revenue Growth (3Y CAGR): 18.11%
Revenue Trend (3Y Correlation): 97.3%

Risk via 10d forecast
Volatility	51.5%
Value at Risk 5%th	73.3%
Relative Tail Risk	-13.39%

Reward TTM
Sharpe Ratio	0.16
Alpha	-8.67

Character TTM
Hurst Exponent	0.405
Beta	0.753
Beta Downside	0.587

Drawdowns 3y
Max DD	48.00%
Mean DD	12.20%
Median DD	6.29%

Description: CLBT Cellebrite DI November 08, 2025

Cellebrite DI Ltd. (NASDAQ: CLBT) supplies a comprehensive digital-forensics suite that enables legally sanctioned investigations across all continents. Its flagship products-Inseyets, Pathfinder, Smart Search, and Guardian-cover the full evidence lifecycle from acquisition and decoding to automated analysis, visualization, and case management, serving law-enforcement, border-control, and corporate security agencies tackling crimes such as child exploitation, terrorism, human trafficking, and cryptocurrency fraud.

In FY 2023 the company reported revenue of $215 million, up roughly 23 % year-over-year, with subscription-based recurring revenue now representing about 70 % of total sales and a gross margin near 78 %. Growth is being driven by expanding government budgets for cyber-crime response and the broader digital-forensics market, which is projected to compound at ~11 % annually through 2028. Cellebrite’s recent rollout of Endpoint Inspector and Endpoint Mobile Now extends its addressable enterprise base, adding a recurring-revenue stream beyond traditional law-enforcement contracts.

For a deeper quantitative assessment, you may find ValueRay’s analyst notes on CLBT useful.

CLBT Stock Overview

Market Cap in USD	4,713m
Sub-Industry	Application Software
IPO / Inception	2021-08-31
Return 12m vs S&P 500	-9.21%
Analyst Rating	4.75 of 5

CLBT Dividends

Currently no dividends paid

CLBT Growth Ratios

CAGR 3y	59.93%
CAGR/Max DD Calmar Ratio	1.25
CAGR/Mean DD Pain Ratio	4.91
Current Volume	1897k
Average Volume	1286.2k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-150.9m TTM) > 0 and > 6% of Revenue (6% = 26.2m TTM)

FCFTA 0.17 (>2.0%) and ΔFCFTA 0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 80.48% (prev 63.05%; Δ 17.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.18 (>3.0%) and CFO 152.7m > Net Income -150.9m (YES >=105%, WARN >=100%)

Net Debt (-180.7m) to EBITDA (72.4m) ratio: -2.49 <= 3.0 (WARN <= 3.5)

Current Ratio 2.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (244.5m) change vs 12m ago 17.14% (target <= -2.0% for YES)

Gross Margin 84.38% (prev 84.19%; Δ 0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 59.68% (prev 57.61%; Δ 2.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.27 (EBITDA TTM 72.4m / Interest Expense TTM 225.3m) >= 6 (WARN >= 3)

Altman Z'' 2.62

(A) 0.42 = (Total Current Assets 668.4m - Total Current Liabilities 316.9m) / Total Assets 834.3m

(B) -0.13 = Retained Earnings (Balance) -107.8m / Total Assets 834.3m

(D) -0.28 = Book Value of Equity -107.8m / Total Liabilities 386.6m

Total Rating: 2.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 80.00

1. Piotroski 5.0pt = 0.0

2. FCF Yield 3.13% = 1.57

3. FCF Margin 31.85% = 7.50

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -2.49 = 2.50

6. ROIC - WACC (= 6.10)% = 7.63

7. RoE -38.81% = -2.50

8. Rev. Trend 97.32% = 7.30

9. EPS Trend 70.14% = 3.51

What is the price of CLBT shares?

As of November 18, 2025, the stock is trading at USD 18.17 with a total of 1,896,978 shares traded.
Over the past week, the price has changed by +16.40%, over one month by -0.06%, over three months by +12.44% and over the past year by +4.01%.

Is Cellebrite DI a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Cellebrite DI (NASDAQ:CLBT) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 80.00 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLBT is around 20.49 USD . This means that CLBT is currently undervalued and has a potential upside of +12.77% (Margin of Safety).

Is CLBT a buy, sell or hold?

Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.

Strong Buy: 6
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CLBT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	24.4	34.5%
Analysts Target Price	24.4	34.5%
ValueRay Target Price	22.9	26%

CLBT Fundamental Data Overview November 15, 2025

Market Cap USD = 4.71b (4.71b USD * 1.0 USD.USD)
P/E Trailing = 50.7368
P/E Forward = 37.1747
P/S = 10.7924
P/B = 10.5283
Beta = 1.284
Revenue TTM = 436.7m USD
EBIT TTM = 61.9m USD
EBITDA TTM = 72.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.25m USD (from shortTermDebt, last fiscal year)
Debt = 11.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -180.7m USD (from netDebt column, last fiscal year)
Enterprise Value = 4.44b USD (4.71b + Debt 11.0m - CCE 281.4m)
Interest Coverage Ratio = 0.27 (Ebit TTM 61.9m / Interest Expense TTM 225.3m)
FCF Yield = 3.13% (FCF TTM 139.1m / Enterprise Value 4.44b)
FCF Margin = 31.85% (FCF TTM 139.1m / Revenue TTM 436.7m)
Net Margin = -34.56% (Net Income TTM -150.9m / Revenue TTM 436.7m)
Gross Margin = 84.38% ((Revenue TTM 436.7m - Cost of Revenue TTM 68.2m) / Revenue TTM)
Gross Margin QoQ = 84.39% (prev 83.74%)
Tobins Q-Ratio = 5.33 (Enterprise Value 4.44b / Total Assets 834.3m)
Interest Expense / Debt = 12.30% (Interest Expense 1.35m / Debt 11.0m)
Taxrate = 6.32% (1.31m / 20.8m)
NOPAT = 57.9m (EBIT 61.9m * (1 - 6.32%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.02 (Debt 11.0m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -2.49 (Net Debt -180.7m / EBITDA 72.4m)
Debt / FCF = -1.30 (Net Debt -180.7m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.09% (Net Income -150.9m / Total Assets 834.3m)
RoE = -38.81% (Net Income TTM -150.9m / Total Stockholder Equity 388.9m)
RoCE = 15.07% (EBIT 61.9m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.90% (NOPAT 57.9m / Invested Capital 388.9m)
WACC = 8.80% (E(4.71b)/V(4.72b) * Re(8.79%) + D(11.0m)/V(4.72b) * Rd(12.30%) * (1-Tc(0.06)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.16%
[DCF Debug] Terminal Value 79.05% ; FCFE base≈123.0m ; Y1≈151.7m ; Y5≈258.9m
Fair Price DCF = 15.64 (DCF Value 3.82b / Shares Outstanding 244.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 70.14 | EPS CAGR: 22.57% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.32 | Revenue CAGR: 18.11% | SUE: 0.39 | # QB: 0

Additional Sources for CLBT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle